Phil Secures $25 Million Series B Funding to Expand Specialty Pharmacy Management Platform

VCBeat (WeChat Official Account: vcbeat) learned from foreign media reports that Phil, a developer of specialty medication management platforms, announced on May 15 the completion of a $25 million Series B financing round. The round was led by new investor GreatPoint Ventures, with participation from Tarsadia Investments, Crosslink Capital, and Uncork Capital. The funds will be primarily used to recruit technical talent and expand business operations to drive the company’s growth.

Phil has developed the only end-to-end health technology platform dedicated to the sale and management of prescription medications, connecting patients, prescribers, pharmacies, and manufacturers by building a modern specialty drug distribution network. The platform aims to reduce communication costs, enable physicians to focus on patient care, and improve patient outcomes.

Specialty drugs refer to medications used to treat complex conditions, such as rheumatoid arthritis and HIV/AIDS, and are subject to stricter regulations than other pharmaceuticals. In today’s world, physicians, pharmacy staff, and patients taking specialty medications are all constrained by inefficient communication models and manual workflows. Healthcare costs continue to rise, while treatment outcomes remain unsatisfactory. In response, Phil has developed a prescription management platform that offers a comprehensive solution, eliminating pain points for patients, providers, and pharmacy personnel by establishing a modernized medication network. Phil believes that medication management challenges cannot be addressed by focusing on only one stakeholder within the drug supply chain.

Deepak Thomas, Founder and CEO of Phil, stated, “Phil provides a systemic solution. The challenges associated with specialty drug management are not confined to the pharmaceutical industry; other stakeholders, including prescribing physicians and manufacturers, face these same issues, and Phil aims to address them holistically. We are delighted to partner with firms such as GreatPoint Ventures and Tarsadia Investments to bring benefits to the healthcare industry.”

Although specialty drugs account for only a small fraction of prescription medications by volume, their management costs are extremely high. Phil is committed to reducing prescription drug costs by improving the efficiency of specialty drug distribution.

Andrew Perlman, Partner at GreatPoint Ventures, stated, “The healthcare industry and pharmaceutical supply chain are in urgent need of modernization. GreatPoint is pleased to support Phil in developing new approaches to specialty drug distribution and management. Phil’s platform enables patients to purchase medications more conveniently at lower prices.”

Phil is in a phase of rapid development, with its revenue increasing 15-fold in 2018 and projected to continue growing exponentially. The company’s team expanded twofold across three office locations last year. Phil has currently established a medication network covering major U.S. states, serving more than 36,000 prescribing physicians, their patients, and major independent pharmacies.

The platform’s automation features streamline user workflows: physicians can manage prescriptions end-to-end with visual tools, boosting work efficiency; independent pharmacies also see improved operational efficiency; and manufacturers’ distribution models become more customer-centric, leading to higher order fulfillment rates and lower overall sales costs.

GreatPoint Ventures, established in 2015 and headquartered in San Francisco, California, is a venture capital firm managing $100 million in assets. The firm primarily participates in Series A and B financing rounds for startups, committed to driving industry transformation, with investment focus areas including software, healthcare, and life sciences.

Tarsadia Investments, founded in 1976 and headquartered in California, USA, is a private equity investment firm. The company primarily provides capital and strategic support to companies with significant growth potential. With over 30 years of investment experience, the Tarsadia Investments team currently manages approximately $2 billion in capital and has completed more than 200 acquisition and divestiture transactions, with a total transaction value exceeding $4 billion.

Crosslink Capital, established in 1989, is one of the earliest and largest investment firms in the United States, specializing in early-stage venture capital. The firm manages approximately $1.6 billion in assets, with its investment funds categorized into three main types: venture capital funds, long/short hedge funds, and hybrid cross-hedge funds.

Uncork, headquartered in California, USA, is a seed-stage venture capital firm focused on investing in innovative technology companies. The firm manages $300 million in assets, with its investment funds divided into two categories: a $100 million seed fund and a $50 million opportunity fund allocated based on assessments of corporate development opportunities. Since 2004, the firm has invested in more than 200 companies.

(Compiled by Tang Lulu)